LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aandelen Lijst・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Gesloten

1.11 -0.89

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.1

Max

1.12

Belangrijke statistieken
By Trading Economics
Inkomsten	17M -26M
Werknemers	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Volgende Winsten	26 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-31M 72M
Vorige openingsprijs	2
Vorige sluitingsprijs	1.11

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.43 / 1.6 Steun & Weerstand

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 feb 2026, 23:21 UTC

Acquisities, Fusies, Overnames

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Marktinformatie

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Winsten

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:58 UTC

Winsten

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 21:35 UTC

Winsten

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 feb 2026, 19:19 UTC

Acquisities, Fusies, Overnames

An S&P Global International Insider Bought Up Stock -- Barrons.com

14 feb 2026, 22:02 UTC

Winsten

Looking for Dividends? Consider Europe. -- Barrons.com

14 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 feb 2026, 21:57 UTC

Winsten

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Winsten

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Marktinformatie

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Marktinformatie

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Marktinformatie

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Winsten

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Acquisities, Fusies, Overnames

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Beoordelingsconsensus

By TipRanks

Sell

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pliant Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.